Compare 8x8 Inc (EGHT) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
8x8 Inc vs Novartis AG — how do they compare? 8x8 Inc trades at $2.05 (market cap $309.09M), while Novartis AG trades at $153.11 (market cap $295.37B). The key difference: Novartis AG is far larger — about 955.6× 8x8 Inc's market cap, and Novartis AG pays a 3.07% dividend while 8x8 Inc pays none. Which is the better fit depends on your goals.
| EGHT | NVS | |
|---|---|---|
Market Cap | $309.09M | $295.37B |
Sector | Technology | Health |
52-Week High | $2.76 | $168.62 |
52-Week Low | $1.59 | $119.31 |
Enterprise Value | $576.02M | $336.69B |
Dividend Yield | — | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EGHT trades at $2.06, down 8.04% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with five consecutive quarters of revenue growth and consistent earnings beats, though profitability remains thin with a 0.64% net margin. Recent AI product expansions and partner program launches signal strategic growth initiatives. Analyst consensus targets $3.13, representing 52% upside potential from current levels.
EGHT presents a compelling risk-reward profile with significant analyst upside but faces execution risks in a competitive communications sector. The transition to profitability in 2026 forecasts and strong institutional support offset near-term volatility concerns. Key risks include high debt levels and margin pressure, while AI adoption growth and consistent earnings outperformance provide catalysts for valuation expansion.
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
